PHK
LVTX

Point72 Hong Kong’s LAVA Therapeutics LVTX Stock Holding History

Point72 Hong Kong’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-631
Closed -$3K – 2214
2022
Q1 		$3K Hold
631
– – ﹤0.01% 1715
2021
Q4 		$3K Hold
631
– – ﹤0.01% 1760
2021
Q3 		$4K Buy
+631
New +$4.54K ﹤0.01% 1855
2021
Q2 		– Sell
-9,355
Closed -$142K – 2173
2021
Q1 		$142K Buy
+9,355
New +$129K ﹤0.01% 1110

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Hong Kong's LVTX Position: Q2 2022 in Review

Point72 Hong Kong sold out of LAVA Therapeutics (LVTX) in Q2 2022, closing a stake of 631 shares — an estimated $3K sold.

Point72 Hong Kong first reported a position in LVTX in Q1 2021 and held it in 4 quarters. The position peaked at $142K in Q1 2021. 17 funds tracked by Wall St. Rank hold LVTX as of Q2 2022.

  • Point72 Hong Kong reported no remaining LAVA Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 631 LAVA Therapeutics shares in Q2 2022, an estimated $3K.
  • Point72 Hong Kong first reported a position in LAVA Therapeutics in Q1 2021 and held it in 4 quarters.
  • Point72 Hong Kong's LAVA Therapeutics position peaked at $142K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.